Alankrita Taneja, MD

With Tec-Dara approved today, options for 1st relapse myeloma continue to expand. Sharing how I currently approach sequencing in clinic, based on emerging data and NCCN discussions. Just one practical framework. Curious how others are thinking about this. #mmsm #hemetwitter

@karabaye14 @grok is this AI

OMG😱😲 What's the cause of this condition??😳😳😭😭

@WomenInLymphoma @PallawiTorkaMD Exciting! Looking forward to it @PallawiTorkaMD

TOMORROW we’re launching our DLBCL webinar series! Join @PallawiTorkaMD and Emily Ayers as they tackle treatment decisions in older patients — a conversation we all need in real-world practice. Register at the link below and save your spot! us06web.zoom.us/webinar/regist…

@UMassChan @UMass @UMassMDPhD @UMass_Medicine @ForHealthCnsltg @UMassChanGiving @UMassDiabetes Please stop torturing animals and not providing them humane care in your lab experiments

What accomplishments and collaborations will UMass Chan Medical School faculty, students and staff have to celebrate in 2026? We will find out together! Happy New Year! #HappyNewYear2026 #UMass @UMass @UMassMDPhD @UMass_Medicine @ForHealthCnsltg @UMassChanGiving @UMassDiabetes

Impact of Duffy genotype on PFS w/ RVd +/- ASCT & continuous R maintenance in Pts w/ NDMM: Updated subgroup analysis of the phase 3 DETERMINATION trial [Nov 3, 2025] @LaurenMerzMD et al. #ASH25 abs25-4186 PID 1033 meetings-api.hematology.org/api/abstract/v… #mmsm #bmtsm #CancerDisparities #globonc

Daratumumab is now FDA and EU approved for treatment of high risk smoldering myeloma. It is recommended level 1 by NCCN. My thoughts: In the AQUILA randomized trial, daratumumab: -Prolonged time to active myeloma -Prolonged time to end organ damage -Delayed time to needing active myeloma therapy -Improved overall survival -Improved PFS-2 -Low toxicity -No detriment to QOL This is a limited duration (3 years) therapy. This limited duration therapy can prevent or delay full blown typically continuous myeloma therapy by years. Full myeloma therapy is not simple. It involves 4 drug initial therapy, stem cell transplant in eligible patients, and prolonged 1-2 drug maintenance. Delaying time to full myeloma therapy by a long time is in and of itself a big deal. Watching patients closely and starting therapy only when you see evidence of progression sounds good on paper but in reality will lead to more patients starting full myeloma therapy sooner. It also risks end organ damage between visits. Experts think they can watch carefully but in studies we find progressions are missed at top centers. In real world the type of follow up we did in AQUILA will not be possible. Patients with active myeloma in my experience are struggling to see their doctors in time. We hope to have more overall survival information soon. But we already see an important improvement. For more on the trial see nejm.org/doi/full/10.10…

This will change my practice. Have seen too many side effects with q4 weekly dosing. jamanetwork.com/journals/jama/…

@pepsi Stop abusing bulls

Si el chisme está bueno… imagínate con Pepsi. ⓘ This user is gossiping. Please use the translate option to stay informed.

@RahulBanerjeeMD We use low dose DOAC, typically eliquis 2.5mg bid if patient is not already on Asa for another reason

Fascinating post hoc pooled analysis of BENEFIT #MMsm trial, so Isa-VRd and Isa-Rd in older ASCT-ineligible myeloma. No carfilzomib. I haven't routinely been using DOACs for VTE PPx in VRd style regimens, but perhaps I will start... 👀 [Their 💊: Apix 2.5 BID or rivarox 10 QD]

@odedanilo Why did I see VISA!!

What is it like to transition from being a #fellow to being an #oncology #attending? Watch as @mhadfield30 and @TanejaMD share their biggest lessons, surprises, and insights from their first year in independent practice! Watch here! youtu.be/Xn6qONCFvcg #hemonc #fellowship

This strategy will likely result in increased step-up administration of bispecific antibodies in the community setting ashpublications.org/bloodadvances/…

Excellent - linvo approved for 🇺🇸 pts with myeloma! 👍🏻 Q2W & Q4W built into approval 👎🏻 FDA forced 4 prior lines again From press release: "0.95 month median time to first response." When I was a kid, time to 1st response with #MMsm BCMA bsAbs was always exactly 1.2 mo 😉

Just out! New IMS/ IMWG Definition of High Risk Myeloma. @JCO_ASCO #IMWG25 @Myeloma_Society @IMFmyeloma @NikhilMunshiMD @mvmateos @SagarLonialMD @szusmani @NoopurRajeMD

My mentee, Chidi, an intern at @TJUHospital Einstein Philadelphia Hospital was awarded the Young Investigator Award at @SocietyofHemOnc for his work on Multiple Myeloma!! So excited for this rising star! 🌟🌟🌟💫

@ZunairahShah @ASCO @ConquerCancerFd @SKabrajiMD @RoswellPark @RoswellHemOnc @KabrajiLab Heartiest congratulations 🎊 👏 💐

Honored to receive the @ASCO @ConquerCancerFd Young Investigator Award!! 🏆 Grateful to my mentor, Dr. Kabraji @SKabrajiMD, for unwavering support and encouragement. @RoswellPark @RoswellHemOnc @KabrajiLab

'Less is more' maintenance therapy in #MultipleMyeloma! Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg) Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence Based on @bdermanmd 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk MRD-neg patients at 3yrs! However, with quad induction + MRD-neg 10^-6 by NGS, do we even need 3yrs of Len? As @End_myeloma reminds us, Len maintenance was built on the backbone of doublets! tinyurl.com/8thww4sz

Had great thought provoking discussions at @LLSusa #myelomarounds #Philadelphia @TJUHospital with Dr Binder and 🌟 fellow Tara

#Myeloma Paper of the Day: Study of outcomes in frail pts getting bispecifics finds best ORR 80% in frail vs 73% in non-frail group; no significant difference in median PFS (NR vs 11 mos) or OS (37 vs 25 mos); similar rates of all grade CRS & ICANS: pubmed.ncbi.nlm.nih.gov/40315372/. #mmsm

@MSKCancerCenter @UrviShahMD @ASH_hematology Congratulations 🎊 So well deserved

Congratulations to MSK's @UrviShahMD for being awarded the @ASH_hematology’s David M. Goldenberg Clinical Research Training Institute Award for her work on research that shows that a high-fiber, plant-based dietary intervention may delay progression #MGUS/#SMM to #MM.